Overview

• Apellis Q3 2025 revenue reached $459 mln, driven by product sales and Sobi payment

• Net income for Q3 2025 was $215.7 mln, boosted by Sobi royalty payment

• Company's cash position strong at $479 mln, expected to fund business to profitability

Outlook

• Apellis expects current cash and revenues to fund operations to profitability

• Company plans pivotal studies for EMPAVELI in rare kidney diseases by year-end 2025

• Apellis anticipates EMA opinion on Aspaveli indication extension by year-end 2025

Result Drivers

• EMPAVELI LAUNCH - Strong early launch of EMPAVELI for C3G and IC-MPGN with 152 new patient start forms received

• SYFOVRE DEMAND - SYFOVRE injection demand grew 4% quarter-over-quarter, maintaining market leadership in geographic atrophy

• SOBI PAYMENT - $275 mln upfront payment from Sobi for royalty purchase agreement significantly boosted revenue

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Apellis Pharmaceuticals Inc is $35.00, about 14.1% above its October 29 closing price of $30.05

Press Release: ID:nGNX3JrQZ6

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)